11/28 Business Wire Health: Biotechnology News

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Business Wire Health: Biotechnology News PanGenex Provides Updated Time Line for Direct Response Television Program with Partner Incredible Discoveries® to Promote Scientifically Formulated, Condition Specific Dietary Supplements November 27, 2009 at 4:00 pm CLEARWATER, Fla.--(BUSINESS WIRE)--PanGenex Corporation (Pink Sheets:PGCX) (“PanGenex” or “the Company”) announced today that it anticipates the release of its long form television program, demonstrating the benefits of Calci-CLEAR™, its patent pending dietary supplement that addresses soft tissue calcification, pursuant to its partnership with Incredible Discoveries® in early 2010. Calci-CLEAR™ is a dietary supplement designed to address soft tissue calc Phase Forward to Present at the 21st Annual Piper Jaffray Health Care Conference November 27, 2009 at 10:45 am WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its chairman and chief executive officer, Bob Weiler, and senior vice president and chief financial officer, Chris Menard, will present at the 21st Annual Piper Jaffray Health Care Conference at the New York Palace Hotel in New York City. The Phase Forward presentation is scheduled for Tuesday, December 1, 2009 at 12:30 p.m. ET. The p Company Profile for HydroMentia, Inc. November 27, 2009 at 10:40 am --(BUSINESS WIRE)--HydroMentia, Inc. is a water pollution control company. It provides innovative, cost-effective solutions that restore and protect waterways overburdened with nutrient pollutants. HydroMentia’s engineers and scientists are pioneers in the development and application of aquatic plant-based water treatment systems. The company’s engineers and scientists applied over sixty years collective experience developing the Algal Turf Scrubber®, a system that provides natu Media Files ViewMedia?mgid=205428&vid=2 (2 KB) Simulations Plus Sets Date for Fiscal Year 2009 Earnings Release and Conference Call November 27, 2009 at 9:25 am LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of software for pharmaceutical discovery and development, announced that it expects to file its 10K-SB annual report with the Securities and Exchange Commission on Monday, November 30, for the 2009 fiscal year ended August 31, 2009. Chairman and CEO Walt Woltosz will host a conference call and webinar to discuss the Company’s performance on Monday afternoon, November 30, at 1:15 PM PST / 4:15 PM EST Media Files ViewMedia?mgid=70096&vid=2 (2 KB) ChemGenex's Marketing Authorization Application for Omacetaxine Mepesuccinate Validated by the European Medicines Agency November 27, 2009 at 8:00 am MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid. Validation of the MAA indicates that ChemGenex’s application, submitted Celgene Corporation to Present at the NASDAQ OMX 23rd Investor Program November 27, 2009 at 7:30 am SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the NASDAQ OMX 23rd Investor Program on Tuesday, December 1, 2009 at 8:30 a.m. GMT will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily Media Files ViewMedia?mgid=127432&vid=2 (2 KB) Tripep Carries out a Rights Issue November 27, 2009 at 6:02 am STOCKHOLM--(BUSINESS WIRE)--The Board of Directors of Tripep AB (publ)(STO:TPEP) has on the 27th of November 2009, based on the authorization by the Annual General Meeting resolved to carry out a rights issue. Every existing share entitles to subscribe for one new share during the period 7 – 21 December 2009 at the subscription price SEK 0.50. If the rights issue is subscribed in full it will give the company a capital injection of SEK 17.8 m (before transaction costs which is estimated to GE医疗集团宣布在俄罗斯生产高科技医疗成像设备的计划‘��并在莫斯科开设培训中心 November 27, 2009 at 5:57 am 莫斯科--(BUSINESS WIRE)--通用电气公司（纽约证券交易所：GE）旗下GE医疗集团（GE Healthcare）与俄罗斯领先的医疗成像设备制造商医疗技术有限公司（Medical Technologies Limited，简称MTL）ߡ Media Files ViewMedia?mgid=206347&vid=2 (2 KB) GE Healthcare gibt Pläne zur Herstellung hochtechnologischer Geräte zur medizinischen Bildgebung in Russland bekannt und eröffnet Schulungszentrum in Moskau November 27, 2009 at 5:48 am MOSKAU--(BUSINESS WIRE)--GE Healthcare, eine Geschäftseinheit der General Electric Company (NYSE:GE), und ein führender russischer Hersteller medizinischer Bildgebungstechnologie, Medical Technologies Limited (MTL), verkündeten heute eine strategische Partnerschaft zur Herstellung diagnostischer Bildgebungsprodukte in Russland im Rahmen der „healthymagination“-Strategie von GE. Das erste Produkt, das aus dieser Partnerschaft hervorgeht, ist das CT-System BrightSpeed Media Files ViewMedia?mgid=206347&vid=2 (2 KB) GE Healthcare annonce son intention de fabriquer de l'équipement d'imagerie médicale de haute technologie en Russie et ouvre un centre de formation à Moscou November 27, 2009 at 5:48 am MOSCOU--(BUSINESS WIRE)--GE Healthcare, une division de General Electric Company (NYSE : GE), et Medical Technologies Limited (MTL), un fabricant russe de premier plan de matériel d'imagerie médicale, ont annoncé aujourd'hui un partenariat pour la fabrication de produits d'imagerie médicale en Russie, à commencer par le système de tomographie assistée par ordinateur BrightSpeed™ Elite1, in line with GE’s healthymagination strategy. The partnership w Media Files ViewMedia?mgid=206347&vid=2 (2 KB) Research and Markets: Parkinson Disease Therapy Area Pipeline Report November 27, 2009 at 5:03 am DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4bfafd/parkinson_disease) has announced the addition of the "Parkinson Disease Therapy Area Pipeline Report" report to their offering. Life Science Analytics, Parkinson Disease Therapy Area Pipeline Report contains detailed information on the parkinson disease drug pipeline. This report provides insight into the pipeline status of parkinson disease drugs by company and by stage as well as a summary of the l AustCham: Australia–China Business Awards 2009 Finalists Announced November 27, 2009 at 4:48 am BEIJING--(BUSINESS WIRE)--The China-Australia Chamber of Commerce Beijing today announced the Finalists of the AustCham Australia-China Business Awards 2009 (ACBA:09). The Finalists in the six judged award categories are: BUSINESS EXCELLENCE Large Companies (>100 employees)     ANZ   www.anz.com/china Bovis Lend Lease   www.bovislendlease.com Elders Limited   www.elders.com.cn/en Hassell   www.hassell.com.au Hooker Cockram   www.hookercockram.com Telstra Sen Media Files ViewMedia?mgid=206384&vid=2 (2 KB) Sectra Signs Partnership Agreement with Leading Spanish Medical Distributor November 27, 2009 at 4:09 am STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Sectra (STO:SECTB) has signed a partnership agreement with the Spanish company Fundación García Muñoz S.L. Founded in 1920, Fundación García Muñoz is a leading supplier of medical equipment and has an extensive customer base in both the private and public healthcare sectors in Spain. Through this partnership, Fundación García Muñoz has become a distributor of complete system for digital mammography includin Major European Regulatory Milestone in Cardiovascular Protection for MICARDIS® (telmisartan): Now Approved by the European Commission to Reduce the Risk of Cardiovascular (CV) Morbidity in High CV Risk Patients November 27, 2009 at 4:00 am INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today that the European Commission has approved MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity in patients with: I. manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or, II. type 2 diabetes mellitus with documented target organ damage. MICARDIS® is the first treatment in its class to be approved for this indication. The EM Media Files ViewMedia?mgid=206363&vid=2 (2 KB) Tripep: The ChronVac-C® Study Has Been Successfully Completed with Good Safety and Favorable Clinical Data November 27, 2009 at 2:22 am STOCKHOLM, Sweden--(BUSINESS WIRE)--All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep’s therapeutic vaccine ChronVac-C® have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus. This provides a proof-of-concept for the therapeutic strategy. In addition, early data from three patients who have initiated standard of care treatment after completing the clinical trial   This email was sent to billionlys.asdf1234@blogger.com.  Manage Your Account Don't want to receive this feed any longer? Unsubscribe here.